Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Sphere 3D Corp. stock logo
ANY
Sphere 3D
$0.59
+9.3%
$0.63
$0.36
$1.90
$16.60M3.22638,811 shs776,984 shs
BTC Digital Ltd. stock logo
BTCT
BTC Digital
$2.78
-0.5%
$3.13
$1.32
$26.58
$20.85M5.051.21 million shs268,473 shs
9F Inc. Sponsored ADR stock logo
JFU
9F
$1.90
-0.2%
$1.53
$1.01
$3.60
$22.30M1.0810,420 shs2,538 shs
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
$0.63
-1.1%
$0.67
$2.08
$4.41
$5.44M-0.2639,605 shs29,754 shs
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Sphere 3D Corp. stock logo
ANY
Sphere 3D
+6.38%+1.34%-23.29%-33.71%-38.17%
BTC Digital Ltd. stock logo
BTCT
BTC Digital
+5.68%+1.82%-34.35%-31.62%+78.85%
9F Inc. Sponsored ADR stock logo
JFU
9F
+2.72%+19.24%+20.38%+38.97%+5.59%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
+1.35%+7.04%-11.09%-1.78%-82.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Sphere 3D Corp. stock logo
ANY
Sphere 3D
2.0489 of 5 stars
3.52.00.00.03.00.00.6
BTC Digital Ltd. stock logo
BTCT
BTC Digital
0.4196 of 5 stars
0.02.00.00.02.00.01.3
9F Inc. Sponsored ADR stock logo
JFU
9F
1.4277 of 5 stars
0.05.00.00.02.21.70.6
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Sphere 3D Corp. stock logo
ANY
Sphere 3D
3.00
Buy$3.00411.07% Upside
BTC Digital Ltd. stock logo
BTCT
BTC Digital
0.00
N/AN/AN/A
9F Inc. Sponsored ADR stock logo
JFU
9F
0.00
N/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest NRBO, BTCT, JFU, and ANY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/12/2025
9F Inc. Sponsored ADR stock logo
JFU
9F
Weiss Ratings
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSell (E+) ➝ Sell (D)
5/21/2025
Sphere 3D Corp. stock logo
ANY
Sphere 3D
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$3.00 ➝ $3.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Sphere 3D Corp. stock logo
ANY
Sphere 3D
$10.83M1.53N/AN/A$1.15 per share0.51
BTC Digital Ltd. stock logo
BTCT
BTC Digital
$11.68M1.79$0.27 per share10.12$6.20 per share0.45
9F Inc. Sponsored ADR stock logo
JFU
9F
$42.47M0.53$0.76 per share2.50$42.74 per share0.04
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/A$1.50 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Sphere 3D Corp. stock logo
ANY
Sphere 3D
-$9.47M-$0.61N/AN/AN/A-131.43%-47.27%-41.94%N/A
BTC Digital Ltd. stock logo
BTCT
BTC Digital
-$1.99MN/A0.00N/AN/A-24.34%-9.68%-8.40%8/13/2025 (Estimated)
9F Inc. Sponsored ADR stock logo
JFU
9F
$6.85MN/A0.00N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
-$12.47MN/A0.00N/AN/AN/A-189.12%-122.31%N/A

Latest NRBO, BTCT, JFU, and ANY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Sphere 3D Corp. stock logo
ANY
Sphere 3D
-$0.11-$0.10+$0.01$0.06$4.60 million$3.02 million
5/14/2025Q1 2025
Sphere 3D Corp. stock logo
ANY
Sphere 3D
-$0.26-$0.29-$0.03-$0.32$3.09 million$2.82 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Sphere 3D Corp. stock logo
ANY
Sphere 3D
N/AN/AN/AN/AN/A
BTC Digital Ltd. stock logo
BTCT
BTC Digital
N/AN/AN/AN/AN/A
9F Inc. Sponsored ADR stock logo
JFU
9F
N/AN/AN/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Sphere 3D Corp. stock logo
ANY
Sphere 3D
N/A
6.69
6.69
BTC Digital Ltd. stock logo
BTCT
BTC Digital
0.01
27.50
27.49
9F Inc. Sponsored ADR stock logo
JFU
9F
N/AN/AN/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
N/A
2.41
2.41

Institutional Ownership

CompanyInstitutional Ownership
Sphere 3D Corp. stock logo
ANY
Sphere 3D
17.28%
BTC Digital Ltd. stock logo
BTCT
BTC Digital
7.32%
9F Inc. Sponsored ADR stock logo
JFU
9F
N/A
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.37%

Insider Ownership

CompanyInsider Ownership
Sphere 3D Corp. stock logo
ANY
Sphere 3D
3.60%
BTC Digital Ltd. stock logo
BTCT
BTC Digital
0.22%
9F Inc. Sponsored ADR stock logo
JFU
9F
53.90%
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
1.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Sphere 3D Corp. stock logo
ANY
Sphere 3D
2028.32 million27.30 millionOptionable
BTC Digital Ltd. stock logo
BTCT
BTC Digital
167.52 million7.50 millionNot Optionable
9F Inc. Sponsored ADR stock logo
JFU
9F
74011.77 million5.43 millionNot Optionable
NeuroBo Pharmaceuticals, Inc. stock logo
NRBO
NeuroBo Pharmaceuticals
108.62 million8.53 millionNot Optionable

Recent News About These Companies

NeuroBo Pharmaceuticals rebrands to become MetaVia
NeuroBo Pharmaceuticals Rebrands Amidst Strategic Changes
NeuroBo Pharmaceuticals announces relignment, change name

New MarketBeat Followers Over Time

Media Sentiment Over Time

Sphere 3D stock logo

Sphere 3D NASDAQ:ANY

$0.59 +0.05 (+9.31%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sphere 3D Corp. engages in the bitcoin mining business. It is involved with digital asset mining pool operators to provide computing power to the mining pools. The company is based in Stamford, Connecticut.

BTC Digital stock logo

BTC Digital NASDAQ:BTCT

$2.78 -0.02 (-0.54%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

BTC Digital Ltd. a crypto asset technology company engages in bitcoin mining business. It is also involved in mining machines resale and rental business. The company was formerly known as Meten Holding Group Ltd. and changed its name to BTC Digital Ltd. in August 2023. The company was founded in 2006 and is headquartered in Shenzhen, China.

9F stock logo

9F NASDAQ:JFU

$1.90 0.00 (-0.15%)
As of 01:41 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

9F Inc., together with its subsidiaries, operates internet securities service platform in the People's Republic of China. The company operates through three segments: Technology Empowerment Services, E-commerce business, and Wealth Management. Its products include digital financial accounts that offer online lending, wealth management, and payment facilitation services; revolving and non-revolving loan products to borrowers, as well as traffic referral services to financial institution partners; and a suite of online wealth management products, such as fixed income products, stocks, insurance, bank wealth management products, and mutual funds to investors in various platforms, including Wukong Licai, 9F Wallet, and 9F Puhui. The company also provides payment facilitation and other products and services that help users to pay credit card bills and household bills comprising utility bills; and other value-added services consisting of credit history search, debt consolidation, and user referral services. In addition, it offers technology empowerment services to banking, automobile, securities investment, and insurance industries; and engages in E-commerce business, which offers various categories of merchandise, including 3C products, beauty and skin care products, food, household appliances, and liquor and beverages. It provides its services to borrowers, investors, and financial institutions partners. The company was formerly known as JIUFU Financial Technology Service Limited and changed its name to 9F Inc. in June 2014. 9F Inc. was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

NeuroBo Pharmaceuticals stock logo

NeuroBo Pharmaceuticals NASDAQ:NRBO

$0.63 -0.01 (-1.08%)
As of 08/12/2025

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity. The company's therapeutic programs include ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 for the treatment of cognitive impairment; and Gemcabene for the treatment of dyslipidemia. It has a license agreement with Pfizer Inc. for the research, development, manufacture, and commercialization of Gemcabene. NeuroBo Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.